Food and Drug
Administration
Blood Products Advisory Committee
April 27, 2007
SLIDES
S2_1 - Summary of August 30-31, 2006 Meeting of the DHHS Advisory Committee on Blood Safety and Availability, Jerry Holmberg, Ph.D., Executive Secretary, Advisory Committee on Blood Safety and Availability (pdf)
S2_2 - Summary of December 15, 2006, Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee, Dorothy Scott, M.D., DH, OBRR, FDA (pdf)
S2_3- Summary of FDA’s Risk Communication on Plasma Derived Factor VIII and Factor XI, Mark Weinstein, Ph.D., OBRR, FDA (pdf)
S2_4 - Summary of September 25-26, 2006 FDA Workshop on Molecular Methods in Immunohematology, Sheryl Kochman, DBA, OBRR, FDA (pdf)
S2_5 Introduction, Alan Williams, Ph.D., DBA, OBRR, FDA (pdf)
S2_6 - Clinical and Laboratory Aspects of TRALI, David F. Stroncek, M.D., National Institutes of Health (pdf)
S2_7 - Current Use of Transfusable Plasma, Ravindra Sarode, M.D., University of Texas Southwestern Medical Center (pdf)
S2_8 Review of REDS-II LAPS Study on HLA and Granulocyte Antibody Prevalence in Blood Donors, Steven H. Kleinman, M.D., University of British Columbia (pdf)
S2_9 - American Red Cross Experience with TRALI, Richard J. Benjamin, M.D., Ph.D., American Red Cross (pdf)
S2_11 - Update on WNV Epidemic 2006, Eileen Farnon, M.D., Centers of Disease Control and Prevention (pdf)
S2_12 - Issues for Testing, Maria Rios, Ph.D., DETTD, OBRR, FDA (pdf)
S2_13 - Data in Support of the Current ID-NAT Triggers, Susan Stramer, Ph.D., American Red Cross (pdf)
Up
| AC Home Page